水蒸气热疗后PSA如何变化?系统综述与荟萃分析
PSA呈双相模式:术后1个月早期升高(ΔPSA=+2.38 ng/mL,95%CI 1.62-3.14),3个月后下降,末次随访时ΔPSA=-0.44 ng/mL(95%CI -0.92至0.04),约较基线下降10%但无统计学意义。
要点
- Rezūm术后1个月PSA早期升高约2.38 ng/mL。
- 3个月后PSA逐渐下降,末次随访降幅约10%但无统计学意义。
- PSA变化与急性尿潴留、再干预率、Qmax改善、基线PSA及前列腺体积相关。
核心结论
- Rezūm治疗与可重复的PSA轨迹相关:早期短暂升高,3-12个月后中度下降约10%。
- 晚期PSA变化无统计学意义且处于PSA预期变异范围内,不太可能改变随访策略。
- 了解该模式有助于合理解读BPH微创术后PSA测量值。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南,检索PubMed/MEDLINE、Scopus和Web of Science。
- 采用限制最大似然(REML)随机效应模型,Cochrane Q评估异质性,荟萃回归探索研究层面变量与ΔPSA的关联。
主要发现
- 术后1个月早期升高:2项研究,ΔPSA=+2.38 ng/mL(95%CI 1.62-3.14)。
- 3个月后PSA下降,末次随访:12项研究,ΔPSA=-0.44 ng/mL(95%CI -0.92至0.04),约较基线下降10%。
- 荟萃回归显示ΔPSA与急性尿潴留(β=0.0799,p=0.034)、再干预率(β=-0.226,p=0.026)、Qmax改善(β=-0.0308,p=0.028)、基线PSA(β=-0.536,p<0.001)及基线前列腺体积(β=-0.0861,p=0.002)相关。
关键数值与推荐
- 主要结局为预设时间点(1、3、6、12个月及末次随访)PSA较基线的汇总平均变化(ΔPSA)。
临床怎么用
- Rezūm术后1个月PSA升高属预期现象,不应误判为肿瘤进展。
- 3个月后PSA中度下降约10%但无统计学意义,无需因此改变随访策略。
- 解读BPH微创术后PSA时应结合急性尿潴留、再干预、Qmax改善、基线PSA及前列腺体积等影响因素。
局限性
- 晚期PSA变化无统计学意义,处于PSA预期变异范围内。
- 研究间存在异质性(Cochrane Q评估)。
- 部分时间点研究数量有限(如1个月仅2项研究)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Prostate-specific antigen (PSA) kinetics following minimally invasive surgical therapies (MIST) for benign prostatic hyperplasia (BPH) remain incompletely characterized. Water vapor thermal therapy (Rezūm™) induces targeted tissue ablation and inflammatory remodeling, potentially affecting PSA levels over time. The aim of this review was to quantify PSA changes after Rezūm therapy and explore study-level correlates of PSA dynamics through a systematic review and meta-analysis. METHODS: This systematic review followed PRISMA guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched for studies reporting baseline and post-treatment PSA after Rezūm therapy. The primary outcome was pooled mean change in PSA (ΔPSA) versus baseline at prespecified timepoints (1, 3, 6, 12 months, and last follow-up). Random-effects models using restricted maximum likelihood (REML) were applied, with heterogeneity assessed using Cochrane Q. Meta-regression explored associations between ΔPSA and study-level variables, including acute urinary retention (AUR), reintervention rates, symptom and flow improvements, and prostate volume. RESULTS: Thirteen studies were included. PSA followed a biphasic pattern. At 1 month, an early postoperative increase was observed (2 studies; ΔPSA = +2.38 ng/mL, 95% CI 1.62-3.14). From 3 months onward, PSA levels declined, reaching a moderate but non-statistically significant reduction at the last available follow-up (12 studies; ΔPSA = -0.44 ng/mL, 95% CI - 0.92 to 0.04), corresponding to an approximate 10% decrease from baseline. Meta-regression showed associations between ΔPSA and AUR (β = 0.0799, p = 0.034), reintervention rates (β = -0.226, p = 0.026), Qmax improvement (β = -0.0308, p = 0.028), baseline PSA (β = -0.536, p < 0.001), and baseline prostate volume (β = -0.0861, p = 0.002). CONCLUSIONS: Rezūm therapy is associated with a reproducible PSA trajectory characterized by an early transient increase followed by a moderate decline from 3-12 months (~10%). Because this late change is non-significant and within the expected variability of PSA, it is unlikely to modify follow-up strategy. Awareness of this pattern may support appropriate interpretation of PSA measurements after MIST for BPH.
引用
- Scilipoti P, Chicaud M, Zorzi F, et al. How does PSA change after water vapor therapy? A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2026. PMID: 42838990. doi:10.1038/s41391-026-01162-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。